Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 9/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4735379 | 0.90 | HSP90AB1 (0.51) | HSP90AB1HSP90AA1CYP2C19KCNH2ADORA2A | |
| SCHEMBL4732878 | 0.85 | HSP90AA1 (0.41) | HSP90AB1HSP90AA1CYP2C19KCNH2DHFR | |
| SCHEMBL17336011 | 0.82 | HSP90AA1 (0.50) | HSP90AB1HSP90AA1ADORA2AADORA1 | |
| SCHEMBL23153308 | 0.80 | HSP90AB1 (0.51) | HSP90AB1HSP90AA1CYP2C19MAOANOS3 | |
| SCHEMBL4735575 | 0.79 | GAA (0.39) | HSP90AB1HSP90AA1DHFR | |
| SCHEMBL24055078 | 0.78 | HSP90AB1 (0.49) | HSP90AB1HSP90AA1CYP2C19NR4A2MAOA | |
| SCHEMBL4731523 | 0.76 | HSP90AA1 (0.40) | HSP90AB1HSP90AA1ADORA2AADORA1DHFR | |
| SCHEMBL17349447 | 0.75 | HSP90AA1 (0.39) | HSP90AB1HSP90AA1ADORA2AADORA1DHFR | |
| SCHEMBL17336023 | 0.74 | HSP90AB1 (0.50) | HSP90AB1HSP90AA1CYP2C19MAOANOS3 | |
| SCHEMBL14207911 | 0.74 | ADORA2A (0.34) | HSP90AB1HSP90AA1ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154547-B1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | YUMA THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210363154-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2021-11-25 | — | — | US | disclosed |
| US-10961254-B2 | Pyrimidine compounds and methods using the same | YUMA THERAPEUTICS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10336768-B2 | Pyrimidine compounds and methods using the same | YUMA THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20170107228-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-20 | — | — | US | disclosed |
| US-20170107228-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-20 | — | — | US | disclosed |
| WO-2015192119-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | YUMA THERAPEUTICS, INC. (US) | 2015-12-17 | — | — | WO | disclosed |
| WO-2008059368-A2 | FUSED 2-AMINO PYRIMIDINE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | PFIZER PRODUCTS INC. (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107228-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | HSP90AB2P, HSPH1, HSF1 | HSP90AB1 5/4885HSP90AA1 8/4885CYP2C19 2776/4885 |
| US-20210363154-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | HSP90AB2P, HSF1, HSPH1 | HSP90AB1 4/4885HSP90AA1 7/4885CYP2C19 2672/4885 |
| US-10336768-B2 | Pyrimidine compounds and methods using the same | HSP90AB2P, HSPH1, HSF1 | HSP90AB1 5/4885HSP90AA1 8/4885CYP2C19 2776/4885 |
| US-10961254-B2 | Pyrimidine compounds and methods using the same | HSP90AB2P, HSPH1, HSF1 | HSP90AB1 5/4885HSP90AA1 8/4885CYP2C19 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.